Knight Therapeutics Inc.
TSX:GUD.TODrug Manufacturers - Specialty & Generic
+$0.07 today
- Market cap
- $1.14B
- Beta
- 0.07
- P/E (TTM)
- 164.6
- EPS (TTM)
- $0.06
Volume 0.04M
Average 0.10M
GUD.TO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Knight Therapeutics Inc.TSX: GUD.TO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of CA$13.17M rose 502.7% year over year, ahead of the -49.3% change in trailing-twelve-month net income. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -43.6% a year.
Context
- Net income amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of CA$13.55M (+352.2%) for the fiscal year ending Dec 2026, a step up from the -224.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$13.17M+48.7% QoQ
- Last fiscal yearDec 2025
- -CA$5.37M-224.1% YoY
- LTMMar 2026
- CA$5.61M-49.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +502.7% | +109.2% | -393.5 pp |
| 1 year | -224.1% | +352.2% | +576.3 pp |
| 3-year CAGR | -43.6% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- (5.37M) CAD
- Year-over-year change
- -224.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.37M) | -224.1% |
| FY2024 | 2024-12-31 | 4.33M | +125.7% |
| FY2023 | 2023-12-31 | (16.84M) | +43.7% |
| FY2022 | 2022-12-31 | (29.89M) | -290.7% |
| FY2021 | 2021-12-31 | 15.68M | — |
Net Income vs competitors
How GUD.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -49.3% is the 4th highest of 8, against a peer median of -56.4%.
- Net income amounts to 1.1% of revenue for GUD.TO, versus a peer median of 12.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$263.55M CAD | -56.4% | -28.6% | 84.8% | |
| LTM Mar 2026 | CA$50.24M CAD | -418.7% | -39.5% | 15.8% | |
| LTM Mar 2026 | $31.07M USD | +236.1% | +0.9% | 61.0% | |
| LTM Mar 2026 | CA$25.21M CAD | -249.3% | — | 9.2% | |
| LTM Mar 2026 | $20.19M USD | -71.2% | — | 7.7% | |
| LTM Mar 2026 | CA$8.44M CAD | +276.1% | -36.4% | 12.7% | |
| LTM Mar 2026 | CA$7.3M CAD | +157.0% | +71.4% | 6.1% | |
| LTM Mar 2026 | CA$5.61M CAD | -49.3% | -43.6% | 1.1% | |
| Peer median (excluding GUD.TO) | — | -56.4% | -28.6% | 12.7% | |
Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.68M | (29.89M) | (16.84M) | 4.33M | (5.37M) |
| Depreciation & Amortization | 47.92M | 62.62M | 50.4M | 53.11M | 56.57M |
| Deferred Income Tax | (7.64M) | (17.13M) | (9.13M) | (3.24M) | (3.81M) |
| Stock-Based Compensation | 3.05M | 1.89M | 2.33M | 1.86M | 8.11M |
| Change in Working Capital | 627K | (9.99M) | (28.01M) | (19.62M) | 1.89M |
| Accounts Receivables | 8.59M | (26.42M) | 5.58M | (10.29M) | (26.53M) |
| Inventory | (17.19M) | (11.43M) | 698K | (5.91M) | (17.82M) |
| Accounts Payables | 11.46M | 30.6M | (21.63M) | 632K | 42.11M |
| Other Working Capital | (2.23M) | (2.74M) | (12.66M) | (4.06M) | 4.14M |
| Other Non-Cash Items | (15.01M) | 32.98M | 37.19M | (154K) | 12.91M |
| Operating Cash Flow | 44.62M | 40.48M | 35.94M | 36.28M | 70.3M |
| Capital Expenditures | (224.18M) | (25.82M) | (9.96M) | (31.47M) | (1.91M) |
| Acquisitions (Net) | (220.35M) | 0 | 0 | 0 | (110.05M) |
| Purchases of Investments | (64.32M) | (185.47M) | (334.16M) | (162.57M) | (70.39M) |
| Sales of Investments | 180.54M | 150.54M | 345.47M | 196.12M | 112.43M |
| Other Investing Activities | 223.04M | (2.33M) | 18.99M | (14.12M) | 17.6M |
| Investing Cash Flow | (105.28M) | (63.08M) | 29.34M | 16.96M | (84.11M) |
| Debt Repayment | (14.19M) | 31.49M | (18.02M) | (18.05M) | 23.19M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 511K |
| Common Stock Repurchased | (64.42M) | (30.07M) | (53.48M) | (8.87M) | (6.35M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 297K | (4.18M) | (9.5M) | (6.62M) | (4.34M) |
| Financing Cash Flow | (78.31M) | 1.76M | (81M) | (33.54M) | 13.01M |
| Effect of Forex Changes | (4.66M) | 6.55M | 2.8M | 1.64M | (2.86M) |
| Net Change in Cash | (143.63M) | (14.28M) | (12.92M) | 21.35M | (3.66M) |
| Free Cash Flow | (179.57M) | 14.67M | 25.98M | 4.81M | 68.4M |
Knight Therapeutics Inc.
TSX:GUD.TO
Intrinsic Alpha fair value
Locked
Current Price
$11.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.